Aurelio Mollo

Aurelio Mollo

Auto-generated profile, based on publicly available information

Aurelio Mollo

Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2016 in Nature
Verified
Journal Article
Closed access
PRPaul Raccuglia
Paul Raccuglia
KEKatherine C. Elbert
Katherine C. Elbert
PAPhilip D. F. Adler
Philip D. F. Adler
CFCasey Falk
Casey Falk
MWMalia B. Wenny
Malia B. Wenny
ANAlexander J. Norquist
Alexander J. Norquist

11 March 2022 in Chemical Reviews
Verified
Journal Article
Closed access
Sujeet KumarSujeet Kumar
Sujeet Kumar
AMAurelio Mollo
Aurelio Mollo
DKDaniel Kahne
Daniel Kahne
NRNatividad Ruiz
Natividad Ruiz

4 March 2020 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
FRFrederick A. Rubino
Frederick A. Rubino
AMAurelio Mollo
Aurelio Mollo
Sujeet KumarSujeet Kumar
Sujeet Kumar
EBEmily K. Butler
Emily K. Butler
NRNatividad Ruiz
Natividad Ruiz
DKDaniel E. Kahne
Daniel E. Kahne

12 July 2017 in RSC Advances
Verified
Journal Article
Open access
PDF file
AMAurelio Mollo
Aurelio Mollo
AKA. Nikolai von Krusenstiern
A. Nikolai von Krusenstiern
JBJoshua A. Bulos
Joshua A. Bulos
VUVeronika Ulrich
Veronika Ulrich
KAKarin Akerfeldt
Karin Akerfeldt
LCLouise K. Charkoudian
Louise K. Charkoudian
Complestatin is a non-ribosomal heptapeptide belonging to the glycopeptide antibiotic family that displays anti-complement, anti-HIV integrase, neuroprotective, anti-apoptotic, and antibacterial activities. Development of complestatin as a pharmaceutical agent and biological probe has been stymied by the difficulty in isolating the molecule from its natural source, Streptomyces lavendulae, as well as by the uneconomical and environmentally unfriendly nature of current total synthetic routes. Of particular challenge to the organic chemist is the installation of the biaryl and aryl–ether–aryl linkages that provide complestatin with the structural rigidity responsible for its potent pharmacological properties. Herein, we demonstrate that ComJ, a P450 monooxygenase from the complestatin biosynthetic gene cluster, can catalyse phenolic cross-linking of amino acid side chains in vitro. ComJ acts with high efficiency and low substrate stereoselectivity, a finding which paves the way towards the use of ComJ as a biocatalyst for the chemo-enzymatic synthesis of complestatin and other related molecules. The ability of ComJ to accept peptides of alternative stereochemistries raises intriguing questions about the evolutionary origins of glycopeptide antibiotic biosynthesis and the capacity of S. lavendulae to produce different conformations of complestatin.

4 June 2026 in Chemical Science
Verified
Journal Article
Open access
PDF file
AMAurelio Mollo
Aurelio Mollo
ECEmma Y. Cool
Emma Y. Cool
BSBahar Sakar
Bahar Sakar
KGKushol Gupta
Kushol Gupta
ENElizabeth M. Nolan
Elizabeth M. Nolan
Intradimer disulfide bond formation in human calprotectin increases the susceptibility of the protein scaffold to proteolysis, indicating this oxidative post-translational modification modulates protein lifetime.